Welcome to Kuiper Inc.

With over 30 years of international experience in cell and gene therapy, the founders of Kuiper Inc have established many of the standards used for regulatory development, approval, and commercialization of applied cell therapies.

Who We Are

Kuiper Inc. is a newly formed international biotech company that will facilitate breakthrough therapies transcending international borders.

Through strategic partnerships, a high proficiency in trade compliance, and strong local knowledge of both regulatory environments and health care economics, we plan to help fast track intellectual property to commercialization in foreign markets.

Breakthrough Therapies

Kuiper Inc. is a newly formed international biotech company that will facilitate breakthrough therapies transcending international borders.

Strategic Partnerships

Along with a high proficiency in trade compliance, we plan to help fast track intellectual property to commercialization in foreign markets.

Regulatory Consulting

Kuiper Inc. provides regulatory consulting for the pre-clinical and clinical development of cell and gene therapies through our strong local knowledge of both regulatory environments and health care economics.

Learn more about the services Kuiper Inc. can offer you.

1

Kuiper 001:

Product Candidate for Critical Limb Ischemia (CLI)

Kuiper plans to develop its product candidate, CLBS12, in Japan for conditional approval for regenerative medicine products.

2

Kuiper 002:

Product Candidate for No Option Refractory Disabling Angina (NORDA)

CLBS14 has been studied in Phase 1, Phase 2, and Phase 3 randomized, double-blind placebo-controlled clinical trials.

3

Kuiper 003:

Product Candidate for Coronary Microvascular Dysfunction (CMD)

Product is being studied in a 20-patient proof-of-concept ESCAPE-CMD Phase 2 study at two centers in the United States.

Learn more about how Kuiper Inc can help you.